Acute troglitazone action in isolated perfused rat liver

British Journal of Pharmacology

Volumn 126, Issue 1, 1999, Pages 372-378

  Preininger, Kurt ^a,b   Sting, Harald ^a   Englisch, Rainer ^a   Fürnsinn, Clemens ^a   Graf, Jürg ^a   Waldhäusl, Werner ^a   Roden, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bile secretion; Glucagon; Glucose production; Glycogenolysis; Insulin; Lactate; Liver; Portal pressure; Rat; Troglitazone

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN; LACTIC ACID; ORAL ANTIDIABETIC AGENT; TROGLITAZONE;

ANIMAL TISSUE; ARTICLE; BILE SECRETION; ISOLATED LIVER; LIVER FUNCTION; LIVER PERFUSION; MALE; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT;

ANIMALS; BILE; CATTLE; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MALE; PERFUSION; PORTAL PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0032918508     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702318     Document Type: Article

References (36)

1. AUBOUEF, D., RIEUSSET, J., FAJAS, L., VALLIER, P., FRERING, V., RIOU, J.P., STAELS, B., AUWERX, J., LAVILLE, M. & VIDAL, H. (1997). Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-st in humans. Diabetes, 46, 1319-1327.
2. AULT, A. (1997). Troglitazone may cause irreversible liver damage. Lancet, 350, 1451.
3. BRUNENGRABER, H., BOUTRY, M. & LOWENSTEIN, J.M. (1973). Fatty acid and 3-hydroxysterol synthesis in the perfused rat liver. Including measurements on the production of lactate, pyruvate, -hydroxy-butyrate, and acetoacetate by the fed liver. J. Biol. C/iem., 248, 2656-2669.
4. BURTON, S.D. & ISHIDA, T. (1965). Effect of insulin on potassium and glucose movement in the perfused rat liver. Am. J. Physiol., 209, 1145-1151.
5. CHENG, A., FITZGERALD, T.J. & CARLSON, G.M. (1985). Adenosine 5 1-diphosphate as an allosteric effector of phosphorylase kinase from rabbit skeletal muscle. J. Biol. Cliem., 260, 2535-2542.
6. ECKHARDT, E.T., PLAA, G.L. & DARBY, T.B. (1963). The effect of thioridazine on hepatic blood flow: Arch. Int. Pharmcodyn. Ther., 145, 109-122.
7. FRACASSO, M.F., LEONE, R. & BERTI, T. (1980). Biochemical changes in isolated perfused livers from rats intoxicated with CC14 or fed with steatogenous diet. Pharinacol. Res. Comm., 12, 295-306.
8. FUJIWARA, T., YOSHIOKA, S., YOSHIOKA, T., USHIYAMA, I. & HORIKOSHI, H. (1988). Characterization of a new oral antidiabetic agent CS-o45. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes, 37, 1549-1558.
9. FULGENCIO, J.-P., KOHL, C., GIRARD, J. & PRÉGORIER, J.-P. (1996). Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes, 45, 1556-1562.
10. FÜRNSINN, C, NESCHEN, S., NOE, C, BISSCHOP, M., RODEN, M., VOGL, C., SCHNEIDER, B. & WALDHÄUSL, W. (1997). Acute noninsulin-like stimulation of rat muscle glucose metabolism by troglitazone in vitro. Brit. J. Pharinacol., 122, 1367-1374.
11. GORES, G.J., KOST, L.J. & LARUSSO, N.F. (1986). The isolated perfused rat liver: conceptual and practical considerations. Hepatology, 6, 511 - 517.
12. GRAF, J. & PETERLIK, M. (1976). Ouabain mediated sodium uptake and bile formation by the isolated perfused rat liver. Am. J. Physiol., 230, 876-885.
13. HEMS, D.A. & WHITTON, P.D. (1980). Control of hepatic glycogenolysis. Physiol. Rev., 60, 1-50.
14. IMURA, H. (1998). A novel antidiabetic drug, troglitazone - reason for hope and concern. New Engl. J. Med., 338, 908-909.
15. INZUCCHI, S.E., MAGGS, D.O., SPOLLETT, G.R., PAGE, S.L., RIFE, F.S., WALTON, V. & SHULMAN, G.I. (1998). Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. A 1. Engl. J. Med., 338, 867-872.
16. IWAMOTO, Y., KUZUYA,T., MATSUDA, A., AWATA,T., KUMKURA, S., INOOKA, G. & SHIRASHI, I. (1991). Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care, 14, 10831086.
17. KAWAI, K., KAWASAKI-TOKUI, Y., ODAKA, T., TSURUDA, F., KAZUI, M., IWABUCHI, H., NAKAMURA, T., KINOSHITA, T., IKEDA, T., YOSHIOKA, T., KOMAI, T. & NAKAMURA, K. (1997). Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice, and dogs. Arzneimittel Forsch. Drug Res. ,47,356-368.
18. KHOURSHED, M., MILES, F.D.G., GAO, K.M., LEE, M.K., MOOSS, A.A.R. & OLEFSKY, J.M. (1995). Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. Metabolism, 44, 1626-1630.
19. KRELL, H. & DIETZE, E. (1989). Hemodynamic and metabolic responses to leukotriene C4 in isolated perfused rat liver. Hepatology, 10, 300-305.
20. KREUTTER, O.K., ANDREWS, K.M., GIBBS, E.M., HUTSON, N.J. & STEVENSON, R.W. (1990). Insulin-like activity of new antidiabetic agent CP 68722 in 3T3-L1 adipocytes. Diabetes, 39, 14141419.
21. LEE, M.K., MILES, P.D.G., KHOURSHED, M., GAO, K.M., MOOSSA, A.R. & OLEFSKY, J.M. (1994). Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes, 43,14351439.
22. LEE, M.K. & OLEFSKY, J.M. (1995). Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism, 44, 1166- 1169.
23. LEHMANN, J.M., MOORE, L.B., SMITH-OLIVER, T.A., WILKINSON, W.O., WILLSON, T.M. & KLIEWER, S.A. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor y (PPAR-/). J. Biol. Client.. 270, 12953-12956.
24. NEUSCHWANDER-TETRI, B.A., ISLEY, W.L., OKI, J.C., RAMRAKHIANI, S., QUIASON, S.O., PHILLIPS, N.J. & BRUNT, E.M. (1998). Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann. Intern. Med., 129, 38 -41.
25. NISHIMURA, Y., INOUE, Y., TAKEUCIII, H. & OKA, Y. (1997). Acute effects of pioglitazone on glucose metabolism in perfused rat liver. Acta Diabetol., 34, 206-210.
26. PILKIS, S.J., EL-MAGHRABI, M.R., PILKIS, J., CLAUS, T.H. & GUMMING, D.A. (1990). Fructose 2,6-bisphosphate. A new activator of phosphofructokinase. J. Biol. Chem., 256, 31713174.
27. RAMAN, P., FOSTER, S.E., STOKES, M.C., STRENGE, J.K. & JUDD, R.L. (1998). Effect of troglitazone (rezulin) on fructose 2,6bisphosphate concentration and glucose metabolism in isolated rat hepatocytes. Life Sei., 62, 89-94.
28. RODEN, M., LIENER, K., FÜRNSINN, C., NOWOTNY, P., HOLLENSTEIN, U., VIERHAPPER, H. & WALDHÄUSL, W. (1992). Effects of islet amyloid polypeptide on hepatic insulin resistance and glucose production in the isolated perfused rat liver. Diabetologia,35, 116-120.
29. RODEN, M., PRSKAVEC, M., FÜRNSINN, C., ELMADFA, L, KÖNIG, J., SCHNEIDER, B., WAGNER, O. & WALDHÄUSL, W. (1995). Metabolie effect of sodium selenite: insulin-like inhibition of glucagon-stimulated glycogenolysis in the isolated perfused rat liver. Hepatology, 22, 169- 170.
30. SALTIEL, A.R. & OLEFSKY, J.M. (1996). Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 45, 1661-1669.
31. SCHWARTZ, S., RASKIN, P., FONSECA, V. & GRAVELINE, J.F. (1998). For the Troglitazonc and Exogenous Insulin Study Group. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N. Engl. J. Med., 338, 861-866.
32. SHIBUKAWA, A., SAWADA, T., NAKAO, C., IZUMI, T. & NAKAGAWA.T. (1995). High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma. J. Chromatograph)-, 697, 337-343.
33. TAVOLONI, N., REED, J.S., HRUBAN, Z. & BOYER, J.L. (1979). Effect of chlorpromazine on hepatic perfusion and bile secretory function in the isolated perfused rat liver. J. Lab. Clin. Med., 94,726-741.
34. TEBOUL, L., GAILLARD, D., STACCINI, L., INADERA, H., AMRI, E.Z. & GRIMALDI, P.A. (1995). Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. J. Bio!. Clwm., 270, 28183-28187.
35. VAN SCHAFTINGEN, E. & HERS, H.-G. (1981). Inhibition of fructose1,6-bisphosphatase by fructose-2,6-bisphosphate. Proc. Nail. Acad. Sei. U.S.A., 78, 2861-2863.
36. WATKINS, P.B. & WHITCOMB, R.W. (1998). Hepatic dysfunction associated with troglitazone. N. Engl. J. Med., 338, 916-917.